Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Varian Semiconductor Equipment Associates -- VSEA -- Ignore unavailable to you. Want to Upgrade?

To: Sherman Chen who wrote (1372)	4/26/2001 9:05:51 AM
From: Proud_Infidel	Read Replies (2) \| Respond to of 1929

Varian Semiconductor Attains Number One Market Share Position Dataquest Report Shows Varian Semiconductor as the Leading Ion Implantation Supplier and the Fastest Growing Major Semiconductor Capital Equipment Company GLOUCESTER, Mass.--(BUSINESS WIRE)--April 26, 2001-- Company Gaining Share in All Segments Varian Semiconductor Equipment Associates, Inc. (NASDAQ: VSEA - news), today announced the company has achieved the number one ion implantation supplier position, as well achieving the fastest growing major semiconductor capital equipment company status, according to a report just released by Dataquest. Varian Semiconductor led the industry in the ion implant market with 42 percent overall market share on a unit basis in calendar 2000, up 11 percentage points from calendar 1999. ``With the widespread acceptance of the new VIISta platform of ion implanters we have leveraged our single-wafer advantages to capture market share in the high current and high energy markets, as well as extending our lead in medium current,'' remarked Richard A. Aurelio, Varian Semiconductor's chairman and chief executive officer. ``This across-the-board increase in market share reflects our customers' acceptance of the throughput advantages of single-wafer processing and the economic benefits of our common platform, with its maximum production flexibility.'' The Dataquest research shows that Varian Semiconductor has increased its market share in all three ion implant segments with share gains in units of 6 percent in high current, 3 percent in high energy and 15 percent in the medium current market. Varian Semiconductor realized a majority of these gains through the sales of its new VIISta common platform of ion implanters in both the 200mm and 300mm marketplace. ``Our leadership in 300mm sales should also enable us to capture the next wave of market share gains,'' said Ernie Godshalk, Varian Semiconductor's president and chief operating officer. ``Since technology drives our business, these market share gains demonstrate that VIISta's single-wafer technology advantages provide the performance attributes necessary for the next generation of integrated circuits.'' About Varian Semiconductor Varian Semiconductor Equipment Associates is a leading producer of ion implantation equipment used in the manufacture of semiconductors. The company is headquartered in Gloucester, Massachusetts, and operates worldwide. Varian Semiconductor maintains a web site at www.vsea.com. The information contained in our web site is not incorporated by reference into this release, and our web site address is included in this release as an inactive textual reference only. Note: This press release contains forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. For this purpose, the statements concerning the company's operating outlook, market share and technology leadership are forward-looking statements. There are a number of important factors that could cause actual events to differ materially from those suggested or indicated by such forward-looking statements. These include, among others, volatility in the semiconductor equipment industry; economic conditions in general and as they affect the company's customers; significant fluctuations in the company's quarterly operating results; the impact of rapid technological change and the company's dependence on the development and introduction of new products; the company's concentration on ion implantation systems and related products; concentration in the company's customer base and lengthy sales cycles; the highly competitive market in which the company competes; risks of international sales; foreign currency risks; general economic conditions; and other factors identified in the company's Annual Report on Form 10-K, and the most recent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. The company cannot guarantee any future results, levels of activity, performance or achievement. The company undertakes no obligation to update any of the forward-looking statements after the date of this press release.

To: Sherman Chen who wrote (1372)	5/1/2001 9:12:58 AM
From: Proud_Infidel	Read Replies (1) \| Respond to of 1929

Elizabeth E. Tallett Elected to Varian Semiconductor's Board GLOUCESTER, Mass.--(BUSINESS WIRE)--May 1, 2001--Varian Semiconductor Equipment Associates, Inc. (NASDAQ: VSEA - news) today announced that Elizabeth E. Tallett, president and chief executive of Dioscor, Inc., has been elected to its Board of Directors. Tallett has been CEO of Dioscor since 1996. In addition, she recently founded Galenor, Inc., a cardiovascular medicine company. She is a respected leader in entrepreneurial business, specializing in management and strategic implementation. Her previous responsibilities have included global business management and new business development. ``Liz brings sharp strategic focus, considerable experience growing markets for new products and product development experience to our board,'' said Richard A. Aurelio, chairman and chief executive officer of Varian Semiconductor. ``We look forward to the addition of her ideas, energy and global perspective on our team. We are delighted to welcome her to our board.'' In 1992 Tallett was a founder, president and chief executive officer of Transcell Technologies Inc., a pharmaceutical company. Previously, she held executive positions at Centocor, Inc. and Parke-Davis, the pharmaceutical arm of Warner-Lambert. Tallett is a member of the board of directors of The Principal Mutual Life Insurance Company, Varian, Inc., Coventry Health Care Inc., IntegraMed America Inc. and of Immunicom Inc. She is a founding board member of the Biotechnology Council of New Jersey. Tallett was also appointed to the Prosperity New Jersey Commission by New Jersey's former Governor Christine Todd Whitman. Tallett was born and educated in England. She is a graduate of Nottingham University with dual first class honors degrees in mathematics and economics, specializing in application of statistical methods to management issues. About Varian Semiconductor Varian Semiconductor Equipment Associates is a leading producer of ion implantation equipment used in the manufacture of semiconductors. The company is headquartered in Gloucester, Massachusetts, and operates worldwide. Varian Semiconductor maintains a web site at www.vsea.com. The information contained in our web site is not incorporated by reference into this release, and our web site address is included in this release as an inactive textual reference only. Note: This press release contains forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. For this purpose, the statements concerning the company's intention to repurchase shares of its common stock from time to time under the stock repurchase program and the intended use of any repurchased shares are forward-looking statements. There are a number of important factors that could cause actual events to differ materially from those suggested or indicated by such forward-looking statements. These include, among others, the market price of the company's stock prevailing from time to time, the nature of other investment opportunities presented to the company from time to time, the company's cash flows from operations, general economic conditions, and other factors identified in the company's Annual Report on Form 10-K, and the most recent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. The company cannot guarantee any future results, levels of activity, performance or achievement. The company undertakes no obligation to update any of the forward-looking statements after the date of this press release.

To: Sherman Chen who wrote (1372)	5/7/2001 12:02:05 PM
From: Proud_Infidel	Read Replies (4) \| Respond to of 1929

Varian Semiconductor Receives Order for Multiple Systems From Austria Mikro Systeme International AG GLOUCESTER, Mass.--(BUSINESS WIRE)--May 7, 2001--Varian Semiconductor Equipment Associates, Inc. (NASDAQ: VSEA - news), a leading supplier of ion implantation systems, today announced that Austria Mikro Systeme International AG (AMS) has purchased both medium current EHPi 500 and high current VIISion 80 PLUS ion implanters. These systems will be installed for the first phase of production at the new AMS2000 200mm production line in Unterpremstatten, Austria. ``Varian Semiconductor's EHPi 500 and VIISion 80 PLUS ion implanters will be used in the production of application-specific integrated circuits (ASICs) for automotive, telecommunication and industrial applications,'' said Gerhard Richter, project manager of AMS2000 at Austria Mikro Systeme International AG. ``To meet our customers' needs we implemented a production strategy based on high equipment reliability and flexibility. Both the EHPi 500 and VIISion 80 PLUS offer exceptional flexibility for our ASIC integrated circuit fabs. Varian Semiconductor's tools are world-class industry workhorses that provide the quick change capability we need to manage our large product library. The new 200mm wafer fabrication facility of AMS is furnished with state of the art production equipment and allows implementation of deep submicron technologies. Aside from multiple capacity, AMS will afford its customers a significant increase in innovative solution options of mixed signal ASICs and ASSPs.'' Since its introduction in 1989, Varian Semiconductor's E-Series implanters have been the tools of choice for more medium current installations than any other system - almost 800 to date. The EHPi 500 is best known for its exceptional performance in controlling threshold voltage adjust (Vt) implants, providing wider energy ranges, and high-throughput factory automation compatibility. The VIISion 80 PLUS implanter demonstrates production leadership in the areas of charge control, dose repeatability, and metal and particle performance. ``We are delighted that AMS has chosen Varian Semiconductor as its ion implant supplier at its new 200mm production line,'' stated Ernest Godshalk, president and chief operating officer of Varian Semiconductor. ``It's an exciting time for AMS, and we look forward to providing our advanced technology solutions for their AMS2000 project and to cultivating our new business relationship.'' About Varian Semiconductor Varian Semiconductor Equipment Associates is a leading producer of ion implantation equipment used in the manufacture of semiconductors. The company is headquartered in Gloucester, Massachusetts, and operates worldwide. Varian Semiconductor maintains a web site at www.vsea.com. The information contained in our web site is not incorporated by reference into this release, and our web site address is included in this release as an inactive textual reference only. Note: This press release contains forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. For this purpose, the statements concerning the company's operating outlook, market share and technology leadership are forward-looking statements. There are a number of important factors that could cause actual events to differ materially from those suggested or indicated by such forward-looking statements. These include, among others, volatility in the semiconductor equipment industry; economic conditions in general and as they affect the company's customers; significant fluctuations in the company's quarterly operating results; the impact of rapid technological change and the company's dependence on the development and introduction of new products; the company's concentration on ion implantation systems and related products; concentration in the company's customer base and lengthy sales cycles; the highly competitive market in which the company competes; risks of international sales; foreign currency risks; general economic conditions; and other factors identified in the company's Annual Report on Form 10-K, and the most recent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. The company cannot guarantee any future results, levels of activity, performance or achievement. The company undertakes no obligation to update any of the forward-looking statements after the date of this press release.